Fecal Calprotectin in Patients with Crohn's Disease: A Study Based on the History of Bowel Resection and Location of Disease.

C-reactive protein Crohn’s disease bowel resection disease location fecal calprotectin

Journal

Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402

Informations de publication

Date de publication:
22 Apr 2024
Historique:
received: 21 03 2024
revised: 17 04 2024
accepted: 18 04 2024
medline: 26 4 2024
pubmed: 26 4 2024
entrez: 26 4 2024
Statut: epublish

Résumé

Fecal calprotectin (FC) is commonly used to assess Crohn's disease (CD) activity. However, standardized cut-off values accounting for bowel resection history and disease location are lacking. In this study, we analyzed data from patients with CD who underwent magnetic resonance enterography, ileocolonoscopy, and FC measurements from January 2017 to December 2018. In 267 cases from 254 patients, the FC levels in the 'operated' patients were higher when the disease was active compared with those who were in the remission group (178 vs. 54.7 μg/g;

Identifiants

pubmed: 38667499
pii: diagnostics14080854
doi: 10.3390/diagnostics14080854
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : National Research Foundation of Korea
ID : 2021R1A6A1A03040260

Auteurs

Jeongkuk Seo (J)

Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Republic of Korea.
Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul 06974, Republic of Korea.

Subin Song (S)

Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Republic of Korea.

Seung Hwan Shin (SH)

Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Republic of Korea.

Suhyun Park (S)

Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Republic of Korea.

Seung Wook Hong (SW)

Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Republic of Korea.

Sang Hyoung Park (SH)

Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Republic of Korea.
Inflammatory Bowel Disease Center, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Republic of Korea.

Dong-Hoon Yang (DH)

Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Republic of Korea.

Byong Duk Ye (BD)

Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Republic of Korea.
Inflammatory Bowel Disease Center, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Republic of Korea.

Jeong-Sik Byeon (JS)

Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Republic of Korea.

Seung-Jae Myung (SJ)

Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Republic of Korea.

Suk-Kyun Yang (SK)

Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Republic of Korea.
Inflammatory Bowel Disease Center, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Republic of Korea.

Sung Wook Hwang (SW)

Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Republic of Korea.
Inflammatory Bowel Disease Center, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Republic of Korea.

Classifications MeSH